<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04475406</url>
  </required_header>
  <id_info>
    <org_study_id>2016/009</org_study_id>
    <nct_id>NCT04475406</nct_id>
  </id_info>
  <brief_title>Comparison of Short and Standard Dental Implants</brief_title>
  <official_title>Comparison of Bone Immunological Biomarkers and Microbiological Parameters of Extra Short Dental Implants and Standard Dental Implants Loaded in the Posterior Mandible</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alanya Alaaddin Keykubat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alanya Alaaddin Keykubat University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: This study aimed to evaluate the total amounts of tumor necrosis factor α (TNF-α),&#xD;
      prostaglandin E2 (PGE2), receptor activator of nuclear factor kappa B ligand (RANKL),&#xD;
      receptor activator of nuclear factor kappa B (RANK), and osteoprotegerin (OPG) and the&#xD;
      abundance of putative oral pathogens Fusobacterium nucleatum, Porphyromonas gingivalis,&#xD;
      Treponema denticola, Tannerella forsythia, Prevotella intermedia, and Streptococcus oralis in&#xD;
      extra short and standard dental implants functioning in the posterior mandible.&#xD;
&#xD;
      Methodology: The implants were divided into two groups according to their lengths: standard&#xD;
      (intrabony length ≥8 mm) and extra short (intrabony length ≤ 6 mm). A total of 60 implants&#xD;
      were researched in 30 patients. Probing depth (PD), clinical attachment level (CAL), presence&#xD;
      of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL) were measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION&#xD;
&#xD;
      Dental implants are usually considered an alternative treatment option to replace lost teeth&#xD;
      in edentulous patients. The rate of implant placement in regions more difficult to&#xD;
      rehabilitate has increased with the increase in the success of osseointegration and survival.&#xD;
      However, besides implant placement in sites with insufficient crest width and height,&#xD;
      treatment times and costs have also increased with the use of grafting procedures.1 Various&#xD;
      surgical techniques, such as vertical bone augmentation, sinus floor elevation, and nerve&#xD;
      transposition, have been developed for the treatment of these bone volume insufficiencies.&#xD;
      However, these methods are technically sensitive and can cause significant postoperative&#xD;
      complications. Short dental implants have been suggested as a simpler, cheaper, and faster&#xD;
      alternative to prevent the disadvantages of surgical techniques and for the rehabilitation of&#xD;
      toothless areas.2,3 A large number of randomized controlled clinical trials demonstrated that&#xD;
      the long-term success and survival rates of short implants were similar to those of standard&#xD;
      long implants.4-6 Accumulation of microbial dental plaque around the implant is the most&#xD;
      important cause of implant loss. If the microbial attachment is not removed, diseases such as&#xD;
      peri-implant mucositis and peri-implantitis may occur and result in implant loss in the long&#xD;
      term. Peri-implant mucositis is a reversible inflammatory reaction in the soft tissue&#xD;
      surrounding the implant in function. Peri-implantitis is a microbial inflammatory disease&#xD;
      characterized by the resorption of the supportive bone surrounding the implant in function.7&#xD;
      Gram-negative anaerobic bacteria predominate around the implant sites affected by the&#xD;
      disease. While they resemble chronic periodontal infections, they have a more complex&#xD;
      microbiological character.8 Predominant species around a peri-implantitis implant are red&#xD;
      complex (P. gingivalis, T. denticola, and T. forsythia) and orange complex bacteria (F.&#xD;
      nucleatum and P. intermedia) described by Socransky.9 In 1989, Apse et al. reported a fluid&#xD;
      around the peri-implant sulcus with properties similar to those of the gingival crevicular&#xD;
      fluid, and they called this fluid peri-implant crevicular fluid (PICF).10 The PICF is an&#xD;
      inflammatory exudate formed by osmotic pressure. Biochemical mediators in the PICF are highly&#xD;
      important to determine the health of tissues around the implant.11 Prostaglandins, especially&#xD;
      prostaglandin E2 (PGE2), are considered as a potent mediator of alveolar bone destruction in&#xD;
      periodontitis. A large number of studies reported an increase in PGE2 levels from healthy&#xD;
      state to periodontitis.12 Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine&#xD;
      regulating the Gram-negative bacterial response. The TNF-α concentration is an indicator of&#xD;
      bacterial load and degree of inflammation.13 In areas where peri-implantitis is active, the&#xD;
      presence and activity of osteoclasts are necessary for bone destruction to occur. The&#xD;
      formation and activation of osteoclasts are regulated through the activation of three members&#xD;
      of the TNF family: receptor activator of nuclear factor kappa B ligand (RANKL), receptor&#xD;
      activator of nuclear factor kappa B (RANK), and osteoprotegerin (OPG). Osteoclast&#xD;
      differentiation and activation occur with the binding of RANKL to RANK over the surface of&#xD;
      osteoclasts and precursors. OPG, which is a soluble protein of TNF receptors, antagonizes&#xD;
      RANK-RANKL interaction and increases bone formation by inhibiting osteoclastogenesis. The&#xD;
      levels of proinflammatory cytokines, such as IL-1, IL-6, TNF-α, and PGE2, and RANKL/OPG&#xD;
      rates, which allow the determination of osteoclastic activity, change in the case of&#xD;
      peri-implantitis.14 The aim of this study was to evaluate the levels of TNF-α, PGE2, RANKL,&#xD;
      RANK, and OPG in extra short and standard dental implants functioning in the posterior&#xD;
      mandible. An additional aim was to investigate the levels of putative oral pathogens F.&#xD;
      nucleatum, P. gingivalis, T. denticola, T. forsythia, P. intermedia, and S. oralis in&#xD;
      submucosal biofilm samples from the studied sites.&#xD;
&#xD;
      MATERIALS AND METHODS This study was carried out by recalling individuals whose bilateral&#xD;
      partial tooth losses were treated with implant-supported fixed restorations and whose&#xD;
      implants had been functioning for at least 3 years after prosthetic rehabilitation. The study&#xD;
      was conducted in accordance with the ethical guidelines from the World Medical Association&#xD;
      Declaration of Helsinki (version 2013) (Clinical Researches Ethical Board with the 28. 09.&#xD;
      2016 and 2016/009 decision numbered approval).&#xD;
&#xD;
      A total of 31 patients met the inclusion criteria. One patient did not continue the study.&#xD;
      Further, 60 implants were researched in 30 patients (16 female and 14 male). The bilateral&#xD;
      regions of patients with a standard implant and an extra short implant were grouped into&#xD;
      two.16 Control group: Standard implant, intra-bone length ≥8 mm (30 implants) Test group:&#xD;
      Extra Short implant, intra-bone length ≤6 mm (30 implants)&#xD;
&#xD;
      Collection of clinical data A single calibrated examiner performed all (full-mouth and&#xD;
      site-specific) clinical measurements (B.K.), including probing depth (PD), clinical&#xD;
      attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR),&#xD;
      and bone loss (BL).&#xD;
&#xD;
      The values of PD and BOP were measured from four sites of each implant (mesial, distal,&#xD;
      buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal&#xD;
      probe. The PD was recorded as the distance from the base of the peri-implant to the side of&#xD;
      the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of&#xD;
      bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of&#xD;
      all patients were taken, and differences in the marginal bone level between radiography&#xD;
      images after implant placement and 3 years later were evaluated. Original films and images&#xD;
      taken later were taken with the same angle for standardizaton.&#xD;
&#xD;
      Collection of PICF and subgingival plaque samples After the plaques and soft attachments&#xD;
      around the implants were removed, the implants were isolated using cotton rolls and dried&#xD;
      with an air spray. The PICF was collected from the mesio-buccal region of the implant using&#xD;
      periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the&#xD;
      peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes&#xD;
      containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the&#xD;
      analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.&#xD;
&#xD;
      After collecting the PICF,. the supragingival plaque was carefully removed using a sterile&#xD;
      scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival&#xD;
      plaque samples were collected from the mesio-buccal region of the implant using a sterile&#xD;
      plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were&#xD;
      transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C&#xD;
      until the analysis day.&#xD;
&#xD;
      PICF analysis Commercial enzyme-linked immunosorbent assay kits were used for measuring the&#xD;
      levels of TNF-α, PGE2, RANKL, RANK, and OPG in accordance with the manufacturer's&#xD;
      recommendations (Elabscience Biotechnology Co., Ltd, Wuhan, China). The measuring ranges were&#xD;
      as follows: TNF-α, 7.81-500 pg/mL; PGE2, 31.25-2000 pg/mL; RANKL, 0.16-10 pg/mL; RANK,&#xD;
      0.16-10 pg/mL; and OPG, 0.16-10 pg/mL. Optical density was measured at 450 nm, and the&#xD;
      samples were compared with standards. Biochemical data were measured as the total amount&#xD;
      (pg/30 s).&#xD;
&#xD;
      Genomic DNA preparation An extraction kit was used in accordance with the manufacturer's&#xD;
      recommendations to purify the DNA in the collected plaque samples (GF-1 bacterial DNA&#xD;
      extraction kit, Vivantis, Malaysia). Standards were used for total DNA in the target&#xD;
      bacteria. Genomic DNA was obtained and stored at 4°C.&#xD;
&#xD;
      Real-time polymerase chain reaction Primary probes were determined to define each bacterium&#xD;
      and observe the proliferation curves using real-time polymerase chain reaction (PCR) (Table&#xD;
      1). For the DNA amplification reaction, procedures were performed with a real-time PCR system&#xD;
      (Roche Light Cycler 480 Instrument II, Switzerland) using a master mix (SYBR Green Master&#xD;
      Mix; Life Technologies, CA, USA). PCR cycles were as follows: 10 min at 95°C, 40 cycles at&#xD;
      95°C for 30 s and 2 min at 60°C. DNA contents were calculated using standard curves.&#xD;
&#xD;
      Statistical analysis Statistical analyses were performed with SPSS 19.0 (IBM Inc., IL, USA).&#xD;
      Kolmogorov-Smirnov and Shapiro-Wilk tests were used to examine whether the variables were&#xD;
      normally distributed. The level of significance was used as 0.05 while commenting on the&#xD;
      results.&#xD;
&#xD;
      While examining the differences between the groups, the independent-samples t test was used&#xD;
      when the variables were normally distributed.&#xD;
&#xD;
      The nonparametric Mann-Whitney U test was used when the variables were not normally&#xD;
      distributed. The chi-square analysis was used while examining the relationships between the&#xD;
      groups of nominal variables. The survival rate (CSR) was calculated according to the number&#xD;
      of short and standard implants placed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">March 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the levels of putative oral pathogens (using PCR)</measure>
    <time_frame>an average of 3 year</time_frame>
    <description>An extraction kit was used in accordance with the manufacturer's recommendations to purify the DNA in the collected plaque samples (GF-1 bacterial DNA extraction kit, Vivantis, Malaysia). Standards were used for total DNA in the target bacteria. Primary probes were determined to define each bacterium and observe the proliferation curves using real-time polymerase chain reaction (PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total amount of TNF-α, PGE2, RANKL, RANK, and OPG (using ELISA)</measure>
    <time_frame>an average of 3 year</time_frame>
    <description>Commercial enzyme-linked immunosorbent assay kits were used for measuring the levels of TNF-α, PGE2, RANKL, RANK, and OPG in accordance with the manufacturer's recommendations (Elabscience Biotechnology Co., Ltd, Wuhan, China).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peri-Implantitis</condition>
  <condition>Peri-implant Mucositis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard implant, intra-bone length ≥8 mm (30 implants)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extra Short implant, intra-bone length ≤6 mm (30 implants)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PICF (Periopaper)</intervention_name>
    <description>After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subgingival plaque, Gracey curette (Hu-Friedy)</intervention_name>
    <description>After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical data, williams probe PCPNU (Hu-Friedy)</intervention_name>
    <description>A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).&#xD;
The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Implants placed by the same periodontologist (E.Ö.) functioning for at least 3 years&#xD;
&#xD;
          -  Patients without any systemic disease affecting bone metabolism&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Extra short (6-mm) implants with identical surface properties bilaterally in one area&#xD;
             in the mandibular region and standard (≥8 mm) implants in the other area&#xD;
&#xD;
          -  Placed implants having the same brand (Straumann Standard Plus; Institute Straumann&#xD;
             AG, Basel, Switzerland)&#xD;
&#xD;
          -  Patients with cemented implant prosthesis in which standard abutment was used in the&#xD;
             mandibular posterior region&#xD;
&#xD;
          -  Implants having no additional bone augmentation during implant surgery&#xD;
&#xD;
          -  No periodontal treatment received in the last 3 years&#xD;
&#xD;
          -  Patients under oral hygiene control (plaque score &lt;20%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor oral hygiene (plaque score &gt;20%)&#xD;
&#xD;
          -  Patients with a history of periodontitis&#xD;
&#xD;
          -  Uncontrolled diabetes and other uncontrolled diseases&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Smoking more than 10 cigarettes a day&#xD;
&#xD;
          -  Using alcohol&#xD;
&#xD;
          -  Receiving radiotherapy and chemotherapy&#xD;
&#xD;
          -  Using drugs suppressing the immune system&#xD;
&#xD;
          -  Having a parafunctional habit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bilge Karcı, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Alanya Alaaddin Keykubat University</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alanya Alaaddin Keykubat University</investigator_affiliation>
    <investigator_full_name>Bilge Karcı</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>After 1 years</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04475406
org study id: 2016/009
nct id: NCT04475406
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
Objective: This study aimed to evaluate the total amounts of tumor necrosis factor α (TNF-α),
      prostaglandin E2 (PGE2), receptor activator of nuclear factor kappa B ligand (RANKL),
      receptor activator of nuclear factor kappa B (RANK), and osteoprotegerin (OPG) and the
      abundance of putative oral pathogens Fusobacterium nucleatum, Porphyromonas gingivalis,
      Treponema denticola, Tannerella forsythia, Prevotella intermedia, and Streptococcus oralis in
      extra short and standard dental implants functioning in the posterior mandible.

      Methodology: The implants were divided into two groups according to their lengths: standard
      (intrabony length ≥8 mm) and extra short (intrabony length ≤ 6 mm). A total of 60 implants
      were researched in 30 patients. Probing depth (PD), clinical attachment level (CAL), presence
      of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL) were measured.
INTRODUCTION

      Dental implants are usually considered an alternative treatment option to replace lost teeth
      in edentulous patients. The rate of implant placement in regions more difficult to
      rehabilitate has increased with the increase in the success of osseointegration and survival.
      However, besides implant placement in sites with insufficient crest width and height,
      treatment times and costs have also increased with the use of grafting procedures.1 Various
      surgical techniques, such as vertical bone augmentation, sinus floor elevation, and nerve
      transposition, have been developed for the treatment of these bone volume insufficiencies.
      However, these methods are technically sensitive and can cause significant postoperative
      complications. Short dental implants have been suggested as a simpler, cheaper, and faster
      alternative to prevent the disadvantages of surgical techniques and for the rehabilitation of
      toothless areas.2,3 A large number of randomized controlled clinical trials demonstrated that
      the long-term success and survival rates of short implants were similar to those of standard
      long implants.4-6 Accumulation of microbial dental plaque around the implant is the most
      important cause of implant loss. If the microbial attachment is not removed, diseases such as
      peri-implant mucositis and peri-implantitis may occur and result in implant loss in the long
      term. Peri-implant mucositis is a reversible inflammatory reaction in the soft tissue
      surrounding the implant in function. Peri-implantitis is a microbial inflammatory disease
      characterized by the resorption of the supportive bone surrounding the implant in function.7
      Gram-negative anaerobic bacteria predominate around the implant sites affected by the
      disease. While they resemble chronic periodontal infections, they have a more complex
      microbiological character.8 Predominant species around a peri-implantitis implant are red
      complex (P. gingivalis, T. denticola, and T. forsythia) and orange complex bacteria (F.
      nucleatum and P. intermedia) described by Socransky.9 In 1989, Apse et al. reported a fluid
      around the peri-implant sulcus with properties similar to those of the gingival crevicular
      fluid, and they called this fluid peri-implant crevicular fluid (PICF).10 The PICF is an
      inflammatory exudate formed by osmotic pressure. Biochemical mediators in the PICF are highly
      important to determine the health of tissues around the implant.11 Prostaglandins, especially
      prostaglandin E2 (PGE2), are considered as a potent mediator of alveolar bone destruction in
      periodontitis. A large number of studies reported an increase in PGE2 levels from healthy
      state to periodontitis.12 Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine
      regulating the Gram-negative bacterial response. The TNF-α concentration is an indicator of
      bacterial load and degree of inflammation.13 In areas where peri-implantitis is active, the
      presence and activity of osteoclasts are necessary for bone destruction to occur. The
      formation and activation of osteoclasts are regulated through the activation of three members
      of the TNF family: receptor activator of nuclear factor kappa B ligand (RANKL), receptor
      activator of nuclear factor kappa B (RANK), and osteoprotegerin (OPG). Osteoclast
      differentiation and activation occur with the binding of RANKL to RANK over the surface of
      osteoclasts and precursors. OPG, which is a soluble protein of TNF receptors, antagonizes
      RANK-RANKL interaction and increases bone formation by inhibiting osteoclastogenesis. The
      levels of proinflammatory cytokines, such as IL-1, IL-6, TNF-α, and PGE2, and RANKL/OPG
      rates, which allow the determination of osteoclastic activity, change in the case of
      peri-implantitis.14 The aim of this study was to evaluate the levels of TNF-α, PGE2, RANKL,
      RANK, and OPG in extra short and standard dental implants functioning in the posterior
      mandible. An additional aim was to investigate the levels of putative oral pathogens F.
      nucleatum, P. gingivalis, T. denticola, T. forsythia, P. intermedia, and S. oralis in
      submucosal biofilm samples from the studied sites.

      MATERIALS AND METHODS This study was carried out by recalling individuals whose bilateral
      partial tooth losses were treated with implant-supported fixed restorations and whose
      implants had been functioning for at least 3 years after prosthetic rehabilitation. The study
      was conducted in accordance with the ethical guidelines from the World Medical Association
      Declaration of Helsinki (version 2013) (Clinical Researches Ethical Board with the 28. 09.
      2016 and 2016/009 decision numbered approval).

      A total of 31 patients met the inclusion criteria. One patient did not continue the study.
      Further, 60 implants were researched in 30 patients (16 female and 14 male). The bilateral
      regions of patients with a standard implant and an extra short implant were grouped into
      two.16 Control group: Standard implant, intra-bone length ≥8 mm (30 implants) Test group:
      Extra Short implant, intra-bone length ≤6 mm (30 implants)

      Collection of clinical data A single calibrated examiner performed all (full-mouth and
      site-specific) clinical measurements (B.K.), including probing depth (PD), clinical
      attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR),
      and bone loss (BL).

      The values of PD and BOP were measured from four sites of each implant (mesial, distal,
      buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal
      probe. The PD was recorded as the distance from the base of the peri-implant to the side of
      the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of
      bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of
      all patients were taken, and differences in the marginal bone level between radiography
      images after implant placement and 3 years later were evaluated. Original films and images
      taken later were taken with the same angle for standardizaton.

      Collection of PICF and subgingival plaque samples After the plaques and soft attachments
      around the implants were removed, the implants were isolated using cotton rolls and dried
      with an air spray. The PICF was collected from the mesio-buccal region of the implant using
      periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the
      peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes
      containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the
      analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.

      After collecting the PICF,. the supragingival plaque was carefully removed using a sterile
      scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival
      plaque samples were collected from the mesio-buccal region of the implant using a sterile
      plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were
      transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C
      until the analysis day.

      PICF analysis Commercial enzyme-linked immunosorbent assay kits were used for measuring the
      levels of TNF-α, PGE2, RANKL, RANK, and OPG in accordance with the manufacturer's
      recommendations (Elabscience Biotechnology Co., Ltd, Wuhan, China). The measuring ranges were
      as follows: TNF-α, 7.81-500 pg/mL; PGE2, 31.25-2000 pg/mL; RANKL, 0.16-10 pg/mL; RANK,
      0.16-10 pg/mL; and OPG, 0.16-10 pg/mL. Optical density was measured at 450 nm, and the
      samples were compared with standards. Biochemical data were measured as the total amount
      (pg/30 s).

      Genomic DNA preparation An extraction kit was used in accordance with the manufacturer's
      recommendations to purify the DNA in the collected plaque samples (GF-1 bacterial DNA
      extraction kit, Vivantis, Malaysia). Standards were used for total DNA in the target
      bacteria. Genomic DNA was obtained and stored at 4°C.

      Real-time polymerase chain reaction Primary probes were determined to define each bacterium
      and observe the proliferation curves using real-time polymerase chain reaction (PCR) (Table
      1). For the DNA amplification reaction, procedures were performed with a real-time PCR system
      (Roche Light Cycler 480 Instrument II, Switzerland) using a master mix (SYBR Green Master
      Mix; Life Technologies, CA, USA). PCR cycles were as follows: 10 min at 95°C, 40 cycles at
      95°C for 30 s and 2 min at 60°C. DNA contents were calculated using standard curves.

      Statistical analysis Statistical analyses were performed with SPSS 19.0 (IBM Inc., IL, USA).
      Kolmogorov-Smirnov and Shapiro-Wilk tests were used to examine whether the variables were
      normally distributed. The level of significance was used as 0.05 while commenting on the
      results.

      While examining the differences between the groups, the independent-samples t test was used
      when the variables were normally distributed.

      The nonparametric Mann-Whitney U test was used when the variables were not normally
      distributed. The chi-square analysis was used while examining the relationships between the
      groups of nominal variables. The survival rate (CSR) was calculated according to the number
      of short and standard implants placed.
allocation: Randomized
intervention model: Factorial Assignment
primary purpose: Prevention
masking: None (Open Label)
measure: the levels of putative oral pathogens (using PCR)
time frame: an average of 3 year
description: An extraction kit was used in accordance with the manufacturer's recommendations to purify the DNA in the collected plaque samples (GF-1 bacterial DNA extraction kit, Vivantis, Malaysia). Standards were used for total DNA in the target bacteria. Primary probes were determined to define each bacterium and observe the proliferation curves using real-time polymerase chain reaction (PCR)
measure: total amount of TNF-α, PGE2, RANKL, RANK, and OPG (using ELISA)
time frame: an average of 3 year
description: Commercial enzyme-linked immunosorbent assay kits were used for measuring the levels of TNF-α, PGE2, RANKL, RANK, and OPG in accordance with the manufacturer's recommendations (Elabscience Biotechnology Co., Ltd, Wuhan, China).
arm group label: Control group
arm group type: Sham Comparator
description: Standard implant, intra-bone length ≥8 mm (30 implants)
arm group label: Test group
arm group type: Active Comparator
description: Extra Short implant, intra-bone length ≤6 mm (30 implants)
intervention type: Other
intervention name: PICF (Periopaper)
description: After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
arm group label: Control group
arm group label: Test group
intervention type: Other
intervention name: Subgingival plaque, Gracey curette (Hu-Friedy)
description: After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
arm group label: Control group
arm group label: Test group
intervention type: Other
intervention name: Clinical data, williams probe PCPNU (Hu-Friedy)
description: A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).
The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton.
arm group label: Control group
arm group label: Test group
criteria: 
gender: All
minimum age: 35 Years
maximum age: 66 Years
healthy volunteers: No
last name: Bilge Karcı, Dr.
role: Study Director
affiliation: Alanya Alaaddin Keykubat University
responsible party type: Principal Investigator
investigator affiliation: Alanya Alaaddin Keykubat University
investigator full name: Bilge Karcı
investigator title: Assistant Professor
mesh term: Mucositis
mesh term: Peri-Implantitis
sharing ipd: No
ipd description: After 1 years